Publications
312
Citations
8,690
Est. group size
~18
Recurring co-author estimate
Active years
34
Publishing since 1993
Typically publishes in teams of ~24 · 6% small-team papers (≤3 authors) · across 7 venues
- Multipole nuclear shielding factors of hydrogen atom confined by a spherical cavity
arXiv (Cornell University) · 2025
- INCIDENCE AND PATHOLOGIC OUTCOMES OF CYSTECTOMY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN-UNRESPONSIVE NON–MUSCLE-INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU FOLLOWING TREATMENT WITH NADOFARAGENE FIRADENOVEC-VNCG
Urologic Oncology Seminars and Original Investigations · 2025
- PD48-01 EFFICACY OF NADOFARAGENE FIRADENOVEC-VNCG FOR PATIENTS WITH BACILLUS CALMETTE-GUÉRIN-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER: FINAL RESULTS FROM A PHASE 3 TRIAL
The Journal of Urology · 2024
- Transperineal Versus Transrectal Magnetic Resonance Imaging–targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial
European Urology · 2024
- Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin–Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial
The Journal of Urology · 2024
- Efficacy of intravesical nadofaragene firadenovec-vncg for patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer: 36-month follow-up from a phase 3 trial
European Urology · 2024
- Randomized trial of transperineal versus transrectal prostate biopsy to prevent infection complications.
Journal of Clinical Oncology · 2024
- EFFICACY OF INTRAVESICAL NADOFARAGENE FIRADENOVEC FOR PATIENTS WITH BCG-UNRESPONSIVE CARCINOMA IN SITU OF THE BLADDER: 36-MONTH FOLLOW-UP FROM A PHASE 3 TRIAL
Urologic Oncology Seminars and Original Investigations · 2024
- Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non–muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial
European Urology · 2021
- Applicant perceptions of virtual interviews for society of urologic oncology fellowships during the COVID-19 pandemic
Urologic Oncology Seminars and Original Investigations · 2021
- PD09-02 ANTI-ADENOVIRAL ANTIBODY LEVELS PREDICT NADOFARAGENE FIRADENOVEC RESPONSE IN BCG-UNRESPONSIVE NMIBC: RESULTS FROM A PHASE 3 TRIAL
The Journal of Urology · 2021
- Automated Tuning IO Parameters for Line X-C [Slides]
2021
- Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
The Lancet Oncology · 2020
- SPARED Collaboration: Patient Selection for Partial Gland Ablation in Men with Localized Prostate Cancer
The Journal of Urology · 2019
- Study of Prostate Ablation Related Energy Devices (SPARED) Collaboration: Patient Selection for Partial Gland Ablation in Men with Localized Prostate Cancer.
The Journal of Urology · 2019
- The Journal of Urology×49
- Urology×15
- Urologic Oncology Seminars and Original Investigations×13
- Journal of Clinical Oncology×9
- European Urology×7
- Vipulkumar Dadhania
Medicine · University of Michigan
- Samuel D. Kaffenberger
Medicine · University of Michigan
- George Philips
Medicine · University of Michigan
- Michael O. Koch
Medicine · Indiana University
- Michael Gong
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile